U.S. markets closed

BioVie Inc. (BIVI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
14.14-0.91 (-6.05%)
At close: 4:00PM EDT
Sign in to post a message.
  • W
    WealthMastersClub1
    The NM101 study (NCT04669028) is a pivotal Phase 3, double blind, randomized, placebo-controlled, US multicenter study of NE3107 in 316 subjects with mild to moderate AD. In addition to conventional cognition, memory, functional, behavioral and imaging end points, NM101 will assess measures of glycemic control, brain glucose utilization and systems dysregulation. The basis for the study design was also recently published in a peer-reviewed article in Neurodegenerative Disease Management (https://doi.org/10.2217/nmt-2021-0022). The study will initiate mid 2021 and aims to have data readout by the end of 2022.

    “NM101 is the first double blind, randomized, placebo-controlled Phase 3 trial conducted by any company to test a disease modifying anti-inflammatory insulin sensitizer therapy in subjects with mild to moderate AD,” said Cuong Do, Chief Executive Officer of BioVie. “In prior animal studies and Phase 1 and 2 human clinical trials, NE3107 has demonstrated to be safe and effective at reducing neuroinflammation and insulin resistance, both of which are recognized as important players in AD pathology.”
  • S
    Suresh
    I am confused about one thing - I see this news about phase 3 but I have been digging and find no information on a phase 2 anywhere. Can anyone point me to info on that? I am very interested in seeing the results from phase 2.
  • W
    WealthMastersClub1
    Basis for BioVie’s Phase 3 Clinical Trial of NE3107 in the Treatment of Alzheimer’s Disease Published in Neurodegenerative Disease Management
    Pivotal Phase 3 Trial of NE3107 Expected to Commence in Summer 2021
  • O
    Oscar
    A RIDICULOUSLY low valuation considering the possibility of a curative outcome .
    I’m going to make a comparison of a company that I followed and invested in seven years ago named Acadia Pharmaceuticals. They developed a drug for psicosis in Parkinsons desease that just like many in the field, has limited effectiveness and a lot of side effects including death.
    Years before approval the company had a valuation of 3 Billion just for the expectation of approval. The drug was approved and the company kept somehow the value for a limited indication in an illness that has roughly 1/5 of the patients of Alzheimer’s in the US.
  • W
    WealthMastersClub1
    BioVie Announces Closing of Acquisition of BioPharma Assets from Privately Held NeurMedix
    BioVie, Inc.
    Fri, June 11, 2021, 5:00 AM·2 min read

    BIVI
    +16.61%
    Company Expects to Commence Enrollment in Pivotal Phase 3 Alzheimer’s Trial in Mid-2021

    SANTA MONICA, Calif., June 11, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company") today announced the closing of its previously announced acquisition of the biopharmaceutical assets of NeurMedix, Inc., a privately held clinical-stage pharmaceutical company. The acquired assets include NE3107, a selective inhibitor of inflammatory ERK signaling that reduces neuroinflammation. It is an orally administered first-in-class small molecule that inhibits inflammation-driven insulin resistance and major pathological inflammatory cascades with a novel mechanism of action. There is emerging scientific consensus that both inflammation and insulin resistance play fundamental roles in the development of Alzheimer’s and Parkinson’s Disease, and NE3107 could represent an entirely new medical approach to treating these devastating conditions affecting an estimated 6 million Americans suffering from Alzheimer’s and 1 million from Parkinson’s. The FDA recently authorized a pivotal US Phase 3 clinical trial for NE3107.
    $AVXL $SAVA $ANVS $BIIB
    Bullish
  • W
    WealthMastersClub1
    $BIIB conversation
    2 largely overlooked biotechs in AD, PD prevention/cure
    BioVie Inc. (BIVI) --- BIVI's NE3107, a selective inhibitor of inflammatory ERK signaling that reduces neuroinflammation. It is an orally administered first-in-class small molecule that inhibits inflammation-driven insulin resistance and major pathological inflammatory cascades with a novel mechanism of action. There is emerging scientific consensus that both inflammation and insulin resistance play fundamental roles in the development of Alzheimer’s and Parkinson’s Disease, and NE3107 could represent an entirely new medical approach to treating these devastating conditions affecting an estimated 6 million Americans suffering from Alzheimer’s and 1 million from Parkinson’s. The FDA recently authorized a pivotal US Phase 3 clinical trial for NE3107.

    AC Immune (ACIU) --- Robust and diverse pipeline of nine therapeutic and three diagnostic product candidates has the potential to greatly improve the treatment of a broad spectrum of Alzheimer’s and neurodegenerative diseases. All of the company’s products were discovered utilizing its proprietary SupraAntigen™ and Morphomer™ technology platforms.
    Partners: Eli Lilly, Janssen (a Johnson&Johnson Co.), Genentech (a Roche Co.), Life Molecular Imaging

    $ACIU $BIVI $SAVA $ANVS $LLY $AVXL
  • W
    WealthMastersClub1
    BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®on the Bloomberg Network in the U.S. on this coming Saturday, June 19th, at 7 p.m. local time $ANVS $SAVA $AVXL $BIIB

    To view the interview segment, please visit: https://youtu.be/B9u4xqdT6lc
    Bullish
  • W
    WealthMastersClub1
    BIVI = Higher ROI
    Company Expects to Commence Enrollment in Pivotal Phase 3 Alzheimer’s Trial in Mid-2021
    $BIIB $ANVS $SAVA $AVXL
  • W
    WealthMastersClub1
    Development of BioVie’s NE3107 Asset Featured by the American Diabetes Association
    BioVie Inc.
    Tue, June 29, 2021, 5:00 AM·3 min read

    BIVI
    -1.12%
    NE3107 Featured in the ADA’s Thought Leadership Film Series at Annual Scientific Session

    SANTA MONICA, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neurodegenerative disorders and certain cancers, announced today that a video documentary detailing the development history of the Company’s newly acquired NE3107 asset will be featured in the American Diabetes Association's Thought Leadership Film Series on ADA TV, a production of the ADA providing news and updates for its 81st Annual Scientific Sessions held virtually from June 25-29, 2021.

    The video can be viewed here https://www.youtube.com/watch?v=EziHhgOlQTg
    Bullish
  • W
    WealthMastersClub1
    BioVie Added to Russell Microcap® Index
    SANTA MONICA, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neuro-degenerative disorders and certain cancers, today announced has been added as a member of the broad-market Russell Microcap Index, effective after the US market opens on June 28, as part of the 2021 Russell indexes reconstitution.

    “We are pleased to be included in the upcoming reconstitution of Russell Microcap Index,” said Cuong Do, chief executive officer of BioVie. “Membership in the index provides an opportunity to expand our shareholder base and will hopefully increase liquidity. With our acquisition of the biopharma assets from NeurMedix assets now complete, this is an exciting time for BioVie and we look forward to realizing the
    company’s full potential.”
    https://finance.yahoo.com/news/biovie-added-russell-microcap-index-120000224.html
  • P
    Prestige Worldwide
    Talk about a Volatile stock. This thing is all over the place
  • X
    X
    B. Riley Raises BioBie's PT to $50 on Liver, Neurodegenerative, and Onocology Pipeline, Keeps Buy Rating.

    no mention of AD drug...maybe needs a higher PT
  • W
    WealthMastersClub1
    $BIIB conversation
    Congrats BIIB Longs! Next >>>> A unique approach to treating AD --- a small molecule, orally administered, anti-inflammatory, insulin-sensitizing agent with a novel mechanism of action is entering a pivotal phase 3 clinical trial for the treatment of mild to moderate Alzheimer’s disease. BioVie $BIVI to acquire Neurmedix assets. $SAVA $AVNS $AVXL
    https://finance.yahoo.com/news/biovie-announces-amended-terms-asset-121900612.html
  • X
    Xonder
    What was the Phase 2 clinical trial data for NE3107?
  • W
    WealthMastersClub1
    BioVie Announces First Patient Enrolled in BIV201 Phase 2b Clinical Trial for Ascites
    Bullish
  • W
    WealthMastersClub1
    In a report released May 24, 2021, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on BioVie (BIVI), with a price target of $50.00.
    Bullish
  • W
    WealthMastersClub1
    Institutional holders is growing from zero (other than former CEO TP)
    Ameriprise Financial 91k $1.8M 100% Mar 2021

    swisspartners 54k $1.1M -28% Mar 2021

    Vanguard Group 27k $510k 100% Mar 2021

    Millennium Management 24k $416k 100% Dec 2020

    Geode Capital Management 21k $410k 100% Mar 2021

    Sowell Financial Services 2.0k $26k 100% Mar 2021

    Taken from stockzoa. sorry ymb won't allow the link
    Bullish
  • J
    J-Rock
    Lots of shares are being given away, not sure I am pleased with this deal. It seems current BIVI share holders are taking all the risk, while NeurMedix is getting a huge amount of BIVI shares, initially and for each milestone while not taking on any risk. Also all the trials will be at BIVI's shareholders expense, expect a dilution. It was mentioned in their conference call just now. Sad only one person asking a question in the call.

    Bummer I was just climbing out of the gutter with this stock. Hopefully other people view this as a good thing but at the moment I do not.
  • W
    WealthMastersClub1
    Jan. 15, 2021 B. Riley starts 'largely overlooked' BioVie with Buy, $47 target B. Riley Securities analyst Mayank Mamtani initiated coverage of BioVie with a Buy rating and $47 price target. The analyst believes BioVie, a clinical-stage company developing "innovative" drug therapies for liver disease, is "largely overlooked by Wall Street." The Phase IIb refractory ascites trial is designed to reaffirm "compelling, albeit early," signs of BIV201's differentiated clinical profile, Mamtani tells investors in a research note. He sees a "clear path" to market for BIV201 given the high mortality rate and more than 100,000 hospitalizations in the U.S. each year.
    Bullish
  • W
    WealthMastersClub1
    Expecting analysts upgrade due to acquisition which will be included in the presentation today at 3:00 ET. Phase 3 pivotal clinical study for AD treatment/therapy is huge deal! Just look what happened to $SAVA for a merely Phase 2.
    Bullish